Research
Hormonal
Subcutaneous semaglutide 2.4 mg once weekly produces 15–17% mean weight loss and offers cardioprotection in obesity treatment.
If you have obesity, subcutaneous semaglutide 2.4 mg once weekly is an approved treatment that can help you lose 15–17% of your body weight and may protect your heart. This is significantly more effective than lifestyle changes alone, which often fail to maintain weight loss long-term.
GoodSupportsHIGH confidence
Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15–17% mean weight loss (WL) with evidence of cardioprotection.
Why this rating
Based on approved status and phase 3 trial data cited.
Source
What is the pipeline for future medications for obesity?
Eka Melson et al. · International Journal of Obesity · 2024
DOI 10.1038/s41366-024-01473-y
narrative_reviewCited 286×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →